In vitro skin permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy
- PMID: 12711449
- DOI: 10.1016/s0168-3659(03)00125-1
In vitro skin permeation and retention of 5-aminolevulinic acid ester derivatives for photodynamic therapy
Abstract
In photodynamic therapy (PDT), 5-aminiolevulinic acid (5-ALA) applied topically is converted, via the heme cycle, into protoporphyrin IX (PpIX), a photosensitizing agent, which upon excitation with light can induce tumor destruction. Due to its hydrophilic and zwitterionic characteristics, 5-ALA has limited penetration into the skin. More lipophilic 5-ALA ester derivatives are expected to cross stratum corneum more easily than 5-ALA. According to the determination of the partition coefficients of 5-ALA methyl, n-butyl, n-hexyl and n-octyl esters, these compounds showed an increased affinity to the SC, with 5-ALA hexyl ester and 5-ALA-octyl ester having the highest partition coefficients. Our in vitro skin permeation studies demonstrated an increased permeated amount for hexyl-ALA after 6 h of incubation, compared to other esters and 5-ALA. After 6 h, more 5-ALA-hexyl ester and -octyl ester were retained at viable epidermis and dermis than 5-ALA. According to these results, and considering that the conversion of 5-ALA into PpIX occurs preferentially in epidermis, it can be supposed that topical use of ester derivatives with longer chains (C(6) or C(8)) is an interesting proposal to optimize topical 5-ALA-PDT
Similar articles
-
Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy.Pharm Res. 2006 Feb;23(2):360-6. doi: 10.1007/s11095-005-9261-x. Epub 2006 Jan 1. Pharm Res. 2006. PMID: 16341572
-
Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapy.Eur J Pharm Sci. 2011 Sep 18;44(1-2):149-57. doi: 10.1016/j.ejps.2011.07.003. Epub 2011 Jul 12. Eur J Pharm Sci. 2011. PMID: 21782942
-
Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum.Photochem Photobiol. 2000 Nov;72(5):681-9. doi: 10.1562/0031-8655(2000)072<0681:taoaah>2.0.co;2. Photochem Photobiol. 2000. PMID: 11107855
-
Aminolevulinic acid derivatives and liposome delivery as strategies for improving 5-aminolevulinic acid-mediated photodynamic therapy.Curr Med Chem. 2006;13(10):1157-68. doi: 10.2174/092986706776360888. Curr Med Chem. 2006. PMID: 16719777 Review.
-
Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy.Dermatology. 2009;218(3):193-202. doi: 10.1159/000183753. Epub 2008 Dec 11. Dermatology. 2009. PMID: 19077380 Review.
Cited by
-
Derivatives of 5-aminolevulinic Acid for photodynamic therapy.Perspect Medicin Chem. 2007 Dec 11;1:49-63. Perspect Medicin Chem. 2007. PMID: 19812736 Free PMC article.
-
Oleic acid as optimizer of the skin delivery of 5-aminolevulinic acid in photodynamic therapy.Pharm Res. 2006 Feb;23(2):360-6. doi: 10.1007/s11095-005-9261-x. Epub 2006 Jan 1. Pharm Res. 2006. PMID: 16341572
-
In vitro metabolism of 5-ALA esters derivatives in hairless mice skin homogenate and in vivo PpIX accumulation studies.Pharm Res. 2004 Dec;21(12):2247-52. doi: 10.1007/s11095-004-7677-3. Pharm Res. 2004. PMID: 15648256
-
Gel Formulation of Nabumetone and a Newly Synthesized Analog: Microemulsion as a Photoprotective Topical Delivery System.Pharmaceutics. 2020 May 5;12(5):423. doi: 10.3390/pharmaceutics12050423. Pharmaceutics. 2020. PMID: 32380748 Free PMC article.
-
Development of lapachol topical formulation: anti-inflammatory study of a selected formulation.AAPS PharmSciTech. 2008;9(1):163-8. doi: 10.1208/s12249-007-9002-z. Epub 2008 Jan 25. AAPS PharmSciTech. 2008. PMID: 18446477 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources